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ABSTRACT OF THESIS 
 
 
ANALYSIS OF KENTUCKY MEDICAID MANAGED CARE VERSUS  
FEE-FOR-SERVICE SYSTEMS: MEDICATION ADHERENCE IN PATIENTS WITH 
PREVALENT CHRONIC DISEASES 
 
Objectives: Managed care organizations reduce healthcare costs and may improve patient 
health outcomes by encouraging better control of prevalent chronic diseases. The purpose 
of this study was to determine whether changing from a fee-for-service program to a 
capitated managed care program improved medication adherence for Medicaid patients in 
Kentucky with hypertension, hypercholesterolemia, or type 2 diabetes.   
Methods: We conducted a quasi-experimental study of patients enrolled in Kentucky 
Medicaid to evaluate the impact of transitioning to capitated managed care in November 
2011. Medication adherence was measured using the proportion of days covered (PDC) 
method. Multivariable analyses measured the adjusted differences in adherence as a result 
of the implementation of capitated managed care.  
Results: Adjusted analyses indicate an average decrease in PDC by about 17-22 days of 
therapy coverage in the post-policy time period. However, no significant difference in 
adherence rate changes between the treatment and control populations were observed.  
Conclusions: Results indicate clinically inconclusive evidence regarding the immediate 
effect of the implementation of Medicaid managed care in Kentucky on medication 
adherence rates in patients with prevalent chronic diseases. There is a need to address the 
decline in average adherence rates, and the efficacy of Medicaid managed care based on 
medication adherence.  
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Section One: Introduction 
According to the World Health Organization, poor adherence to chronic disease 
therapies is a worldwide problem.1 Adherence is defined as the ability to follow a 
specified treatment regimen as provided by a healthcare professional in the treatment of 
an illness or disease.1 Poor adherence to long-term therapies severely compromises the 
effectiveness of treatment, making this a critical issue in population health.1 Studies show 
that poor adherence is associated with a higher incidence of hospitalizations among 
patients with hypertension, and increases complications among patients with 
hypertension and hypercholesterolemia.2 All-cause hospitalizations among patients with 
diabetes increase with poor adherence to therapy.2 Medical costs tend to be lower with 
higher levels of medication adherence, and are primarily driven by reductions in 
hospitalization rates.3 Previous studies have examined rates of adherence to medications 
for prevalent chronic diseases, and 10-20% of patients with either hypertension, 
hypercholesterolemia, or type 2 diabetes were found to have less than optimal medication 
adherence, as measured by the medication possession ratio (MPR < 70%).4 Therefore, 
poor adherence to chronic disease medications is an excellent target for health policy 
makers who desire to improve patient health outcomes.  
The Pharmacy Quality Alliance endorses the proportion of days covered (PDC) as 
the preferred method for calculating adherence.5 PDC is calculated using prescription 
claims data by determining the number of days medication was available to a patient, 
divided by the total number of days during the specified time period.6,7 It calculates 
adherence better than the medication possession ratio by adjusting for early fills of 
medication using arrays. A PDC above 0.8 is considered adherent.7,8 In this study, 
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medication adherence will be evaluated using the proportion of days covered (PDC) 
method.7,8 
In the past two decades, managed care has been proven to be an effective way to 
reduce costs and improve the efficiency of health service utilization by controlling 
provider reimbursement rates and reducing unnecessary hospitalizations and emergency 
department visits.9 Managed care organizations (MCOs) have a fundamental interest in 
primary preventative care for long-term cost reduction due to their structure.9,10 MCOs 
will assign patients to a primary care physician within the network, and give these 
providers a capitated payment for each member they enroll.9,10 In comparison with 
traditional fee-for-service (FFS), MCOs can limit provider choices for patients, where 
FFS patients have no restrictions on which providers can be seen.9 Additionally, in 
traditional FFS models, the providers are not restricted to the number of services they 
provide.9 Not all FFS patients have access to a primary care provider, thereby leading to 
increased utilization of unnecessary emergency department visits.10 Patients enrolled in 
MCO plans are encouraged to have regular physician visits and screenings for early 
detection and prevention of disease, thereby encouraging better patient health outcomes 
and more appropriate health care service utilization.9,10  
Medicaid managed care has improved the ability of Medicaid programs to obtain 
better value for their expenditures, while improving provider accessibility and 
accountability,11 but little data is available regarding quality of care in this patient 
population. A case study comparing capitated MCO reimbursement and FFS 
reimbursement found that for-profit capitation models were more cost-effective than FFS 
models for Medicaid patients with severe mental illness.12 Previous studies of shifts to 
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capitated managed care in commercial insurance and Medicare populations suggest that a 
shift from FFS to MCO reimbursement did not fundamentally change the patterns or 
quality of care delivered.13 A study examining health outcomes for patients with 
congestive heart failure showed that there was no significant difference in outcomes and 
quality of care between patients with FFS-based insurance and patients with MCO-based 
insurance through a health maintenance organization.14 Finally, results from one study of 
a Medicare MCO in Pennsylvania showed that patients receiving a common therapeutic 
procedure for the treatment of coronary artery disease had a clinically meaningful long-
term survival benefit in comparison with their FFS counterparts.15  
The National Committee for Quality Assurance (NCQA) provides accreditation 
measures for health plans and is widely accepted as an important industry standard.16 As 
commercial and government-based payers have become increasingly interested in value, 
MCOs are held accountable for quality and cost.16 NCQA developed the Healthcare 
Effectiveness Data and Information Set (HEDIS) to provide tangible, actionable quality 
measures.16,17 By 2012, such measures included improving control of blood pressure, 
cholesterol management in patients with cardiovascular conditions, and comprehensive 
diabetes care.17 Within these measures, adherence to prescribed medication therapy is 
encouraged.17 In November 2011, the state of Kentucky implemented a policy to change 
its Medicaid infrastructure from fee-for-service reimbursement to managed care, in hopes 
of improving the health of its Medicaid patients while lowering costs.18 The purpose of 
this study was to compare patient medication adherence before and after the 
implementation of capitated managed care for Medicaid patients in Kentucky with 
prevalent chronic diseases, including hypertension, hypercholesterolemia, and type 2 
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diabetes. Additionally, this study will be used to inform policy makers of the efficacy of 
the current Medicaid program in improving medication adherence, and its potential to 
improve patient health outcomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Section Two: Methods 
Overview: 
The study took advantage of a natural experiment due to a policy change in the 
Kentucky Medicaid program. We conducted a retrospective study using a pre-policy and 
post-policy treatment and comparison group, and quasi-experimental design to estimate 
the effect of the switch from Medicaid FFS to managed care. We compared adherence 
rates for populations of Medicaid patients age 18-64 with hypertension, 
hypercholesterolemia, and/or type 2 diabetes who were insured by FFS and were 
switched to one of three new MCOs. Only one Medicaid MCO (Region 3) (Appendix A) 
existed prior to November 2011, and patients from this MCO were used as a control 
population to account for historic trends.18 We hypothesized that the implementation of 
Medicaid managed care would improve overall adherence rates to medications indicated 
for prevalent chronic diseases, adjusting for other factors. 
Sample Selection:  
The study sample was drawn from patients in Kentucky receiving medical care 
through Kentucky Medicaid Services during the years 2010 through 2013. Patient 
demographics, eligibility, and medication claims were obtained from the Kentucky 
Medicaid administrative claims dataset. The sample was divided into four groups: the 
pre-policy treatment group, the post-policy treatment group, the pre-policy control group, 
and the post-policy control group. The treatment group represents Kentucky Medicaid 
patients enrolled in FFS before the policy, and patients enrolled in a MCO after the 
policy. The control group represents patients in the Region 3 MCO before and after the 
policy. The time between November 1, 2010 and October 31, 2011 is defined as the pre-
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policy study period. The time between November 1, 2012 and October 31, 2013 is 
defined as the post-policy study period. The 6 months prior to each study period were 
considered the run-in periods for determining prevalent users of medications to ensure 
treatment was initiated prior to the pre-policy and post-policy study periods. This allows 
for an accurate adherence calculation. These time periods were chosen based on data 
availability, and to allow time for transition after the policy implementation.  
In order to be included in the study, patients had to be continuously eligible for 
Medicaid benefits from May 1, 2010 through October 31, 2011 and/or from May 1, 2012 
through October 31, 2013. Next, patients had to have a diagnosis of hypertension (ICD-9 
codes 401.1 or 401.9), hypercholesterolemia (ICD-9 code 272.x), and/or type 2 diabetes 
(ICD-9 codes 250.x0 and 250.x2) (Appendix B), AND have at least one claim for a first-
line prescription medication (Appendix C) indicated for the treatment of their specific 
chronic disease during either of the run-in periods. The inclusion of diagnosis codes is 
intended to validate the use of each medication for the indicated disease. Then, for the 
corresponding pre- or post-policy study period, patients had to have at least one claim for 
a first-line prescription medication indicated for the treatment of their specific chronic 
disease. Finally, patients had to be between the ages of 18 and 64 to eliminate dual 
eligible patients and pediatric patients. Patients in the post-policy study period were 
excluded if they were not assigned to a managed care organization (i.e. the disabled and 
those in waiver programs) or if they were not in the existing Region 3 MCO. Figure 2.1 
depicts the timeline for sample selection and eligibility requirements. Figure 3.1 is a flow 
diagram of the study population specification.  
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Figure 2.1: Timeline for Sample Selection and Eligibility Requirements 
 
Dependent Variables: 
We evaluated medication adherence using the proportion of days covered (PDC) 
method. The dependent variable can either be continuous or dichotomous, where patients 
are adherent if they have a PDC above 0.8. In this study, PDC was measured as a 
continuous variable for increased statistical power. In subsequent studies, PDC will be a 
dichotomous variable, and the proportion of adherent patients will be determined. The 
PDC was calculated separately for each patient in the four included groups: the pre-
policy treatment group, the post-policy treatment group, the pre-policy control group, and 
the post-policy control group. Medication claims for the included medication classes 
were identified using their generic product identifiers (GPI) (Appendix C). Each patient’s 
PDC calculation used all claims for a single medication class as identified by the first 2-4 
numbers in the GPI. Therefore, if patients were switched to another medication in the 
same medication class during the study period, their adherence calculation would account 
for this change in therapy. For patients who had claims for more than one medication 
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class in the same study period, they would have several different PDC calculations. These 
PDCs were averaged to determine the average PDC per patient. Therefore, for the 
analyses in this study, either average PDC per patient or PDC per medication class per 
patient could be used as the dependent variable of interest.  
Independent Variables:   
The independent variables included in the study were demographic, economic, 
and health-related. The primary independent variable of interest was an indicator variable 
determined by whether the individuals were assigned to any managed care organization 
in November 2011 (post-policy treatment group). Patients enrolled in the Region 3 MCO 
served as a managed care control population. The control variables included age 
(continuous variable), gender (dichotomous variable), ethnicity (two dichotomous 
variables describing the two most prevalent populations), and medication class 
(categorical variable) (Appendix D). The medication classes included in the study were 
ACE inhibitors, angiotensin II receptor blockers, beta-blockers, calcium channel 
blockers, thiazide diuretics, antihypertensive combination products, HMG-CoA reductase 
inhibitors (statins), and biguanides (metformin) (Appendix B). These medications were 
included as they were considered first line therapies based on the guidelines active during 
the time of the study, specifically JNC 7 for hypertension, the 2002 NCEP guidelines for 
high blood cholesterol, and the 2009 AACE/ACE guidelines for type 2 diabetes.19,20,21  
Statistical Analysis: 
Descriptive statistics of the adherence measures and control variables, including 
patient demographics and medication class, for each of the four study groups were 
determined. The demographic data were determined per patient. The adherence statistic 
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was calculated as the average PDC per person, and summary statistics for adherence were 
then calculated in each group. Therefore, mean average PDC is the average of each 
patient’s average PDC in that group. Median average PDC is the middle average PDC 
calculation for that group. The medication class statistics represent the number of patients 
receiving each medication class. Several patients took medicines in more than one of 
these medication classes, so the determined frequencies were greater than the sample 
size.  
Bivariable analyses used non-parametric testing strategies, such as the Wilcoxon 
Sign-Rank test, the Kruskal-Wallis test, and generalized linear regression to measure the 
effect of each variable on the change in adherence as a result of the switch from FFS to 
managed care. The multivariable analysis was conducted as a difference-in-difference 
model, where the dependent variable of adherence measures the effect of the policy 
change, or the pre and post average differences in adherence between the treatment and 
control groups (Appendix D). A difference-in-difference model is a multivariable 
generalized least squares regression model where an interaction term between the pre- 
versus post-policy period and the treatment versus control group is the covariate of 
interest, as this represents the true effect of the policy. The interaction captures the 
overall effect on the post-policy treatment group. Sensitivity analyses considered the 
removal of outliers, interaction terms, and transformations to the non-parametric data to 
determine the robustness of results. The final model represents the multivariate model 
with the largest explanation of variation in the outcome. We considered P values < 0.05 
to be statistically significant. This data for this study represent proprietary information 
used for research by the Institute for Pharmaceutical Outcomes and Policy at the 
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University of Kentucky. This study was reviewed and approved by the University of 
Kentucky Health System’s Institutional Review Board. Data analysis was completed 
using SAS Version 9.4.   
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Section Three: Results 
Characteristics of the Study Population: 
 Figure 3.1 depicts the study population obtained from the Kentucky Medicaid 
administrative claims dataset. The final treatment group included 41,683 patients, with 
22,267 patients in the pre-policy treatment group receiving FFS Medicaid, and 19,416 
patients in the post-policy treatment group receiving MCO Medicaid. The final control 
group included 5,373 patients, with 2,531 patients in the pre-policy control group, and 
2,842 patients in the post-policy control group, all receiving MCO Medicaid in Region 3 
in Kentucky.  
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Figure 3.1: Flow Diagram of Study Population Specification  
     
     
     
     
     
      
      
      
     
     
     
     
     
     
      
      
      
 
 
 
 
 
 
 
 
 
Kentucky Medicaid patients with 
continuous eligibility at least 6 months 
prior to and during a study period 
N = 115,397 (Pre-Policy Period) 
N = 100,431 (Post-Policy Period) 
Patients with a diagnosis of hypertension, 
hypercholesterolemia, or type 2 diabetes 
as identified by ICD-9 codes 
N = 60,870 (Pre-Policy Period) 
N = 51,941 (Post-Policy Period)   
Exclude  
N = 54,527 (Pre-Policy Period) 
N = 48,490 (Post-Policy Period) 
patients without desired diagnoses 
Patients with at least one prescription 
claim for a first-line indicated medication 
during run-in period 
N = 28,427 (Pre-Policy Period) 
N = 26,312 (Post-Policy Period) 
Exclude  
N = 32,443 (Pre-Policy Period) 
N = 25,629 (Post-Policy Period) 
patients without medication claims 
during run-in period 
Patients that have at least one 
prescription claims for an indicated 
medication during study period 
N = 28,360 (Pre-Policy Period) 
N = 26,264 (Post-Policy Period) 
Exclude  
N = 67 (Pre-Policy Period) 
N = 48 (Post-Policy Period) patients 
without medication claims during 
study period 
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Figure 3.1: Flow Diagram of Study Population Specification (continued)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclude  
N = 3,562 (Pre-Policy Period) 
N = 4,006 (Post-Policy Period) 
patients younger than 18 or older than 
64, who are not enrolled in managed 
care in the post-policy period 
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N = 24,798 (Pre-Policy Period) 
N = 22,258 (Post-Policy Period) 
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FFS Medicaid 
(Pre-Policy 
Period) 
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Patients with 
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(Post-Policy 
Period) 
N = 19,416 
Patients with 
Region 3 MCO 
Medicaid (Pre-
Policy Period) 
N = 2,531 
Patients with 
Region 3 MCO 
Medicaid 
(Post-Policy 
Period) 
N = 2,842 
 
Treatment Group 
 
Control Group 
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Descriptive Statistics: 
Table 3.1 provides descriptive statistics of the treatment and control groups, in the 
pre-policy and post-policy study periods, separated into four groups. The average age in 
the sample was around 50 years old, with a median of 52 years. This was consistent 
among each of the treatment and control groups. The proportion of male patients was 
balanced in each group, with around 33% of the groups being male. The ethnicity 
variables are the only unbalanced demographic variables in Table 3.1. There were a 
significantly larger proportion of black patients in the control group versus the treatment 
group. The percentage of each medication class represented was variable among the four 
groups. Most patients were taking either ACE inhibitors or angiotensin II receptor 
blockers (around 40-57%), with beta-blockers making up the next most frequently used 
medication class (around 38-51%). The percentage of ACE inhibitors, angiotensin II 
receptor blockers, and beta-blockers increased in the post-policy period for both the 
treatment and control groups. The control group was taking slightly less ACE inhibitors 
and angiotensin II receptor blockers, and slightly more calcium channel blockers than the 
treatment group. In the post-policy period, the frequency of thiazide diuretics and HMG-
CoA reductase inhibitors increased in both the treatment and control groups. Conversely, 
the frequency of biguanides and antihypertensive combination medications remained the 
same in the post-policy period in both the treatment and control groups. Non-parametric 
tests indicated significant differences between each of the covariates by treatment group 
and by pre- versus post-policy time period (p <0.0001). 
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Table 3.1: Descriptive Statistics by Treatment versus Control Group, and by Pre- versus 
Post-Policy Time Period 
Variable FFS à  MCO (Treatment Group) Region 3 MCO (Control Group) 
 
 
N = 47,056 
Pre-Policy 
(FFS Medicaid) 
N = 22,267 
Post-Policy 
(MCO Medicaid) 
N = 19,416 
Pre-Policy 
 
N = 2,531 
Post-Policy 
 
N = 2,842 
Average PDC 
Mean (SD) 
Median (LQ, UQ) 
 
(Min, Max) 
 
0.735 (0.24) 
0.816 (0.59, 
0.93) 
(0.01, 1) 
 
0.689 (0.23) 
0.734 (0.53, 
0.89) 
(0.01, 1) 
 
0.726 (0.23) 
0.795 (0.58, 
0.92) 
(0.05, 1) 
 
0.676 (0.22) 
0.721 (0.54, 
0.85) 
(0.04, 1) 
Age (years) 
Mean (SD) 
Median (LQ, UQ) 
(Min, Max) 
 
50.17 (9.40) 
52 (45, 58) 
(18, 63) 
 
49.95 (8.94) 
51.5 (45, 57) 
(18, 63) 
 
50.78 (9.02) 
52 (46, 58) 
(18, 63) 
 
50.76 (9.02) 
53 (46, 58) 
(18, 63) 
Males 
Frequency (%) 
 
7,688 (34.5%) 
 
6,746 (34.7%) 
 
831 (32.8%) 
 
889 (31.3%) 
Whites 
Frequency (%) 
 
18,215 (81.8%) 
 
15,947 (82.1%) 
 
1,710 (67.6%) 
 
1,830 (64.4%) 
Blacks  
Frequency (%) 
 
1,096 (4.9%) 
 
663 (3.4%) 
 
513 (20.3%) 
 
581 (20.4%) 
ACE Inhibitors 
and Angiotensin 
II Receptor 
Blockers 
Frequency (%) 
 
 
 
 
9,781 (43.9%) 
 
 
 
 
11,170 (57.5%) 
 
 
 
 
1,002 (39.6%) 
 
 
 
 
1,438 (50.6%) 
Beta Blockers 
Frequency (%) 
 
8,851 (39.7%) 
 
9,960 (51.3%) 
 
963 (38.0%) 
 
1,349 (47.5%) 
Calcium 
Channel 
Blockers 
Frequency (%) 
 
 
 
4,235 (19.0%) 
 
 
 
5,118 (26.4%) 
 
 
 
639 (25.2%) 
 
 
 
881 (31.0%) 
Thiazide 
Diuretics 
Frequency (%) 
 
 
3,069 (13.8%) 
 
 
4,102 (21.1%) 
 
 
346 (13.7%) 
 
 
578 (20.3%) 
Antihypertensive 
Combinations 
Frequency (%) 
 
 
2,861 (12.8%) 
 
 
2,637 (13.6%) 
 
 
327 (12.9%) 
 
 
385 (13.5%) 
HMG-CoA 
Reductase 
Inhibitors 
(Statins) 
Frequency (%) 
 
 
 
 
10,067 (45.2%) 
 
 
 
 
12,216 (62.9%) 
 
 
 
 
1,082 (42.7%) 
 
 
 
 
1,699 (59.8%) 
Biguanides 
(Metformin) 
Frequency (%) 
 
 
6,957 (31.2%) 
 
 
5,882 (30.3%) 
 
 
793 (31.3%) 
 
 
882 (31.0%) 
Means and standard deviations (in parentheses) are given for continuous variables, whereas 
frequencies and percentages (in parentheses) are given for categorical variables.  
FFS = Fee-For-Service; MCO = Managed Care Organization; PDC = proportion of days covered  
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 Average PDC values are similar between the pre-policy treatment group and pre-
policy control group. In addition, average PDC values are similar between the post-policy 
treatment group and post-policy control group. However, average PDC values in the pre-
policy period are larger in magnitude than in the post-policy period, regardless of 
treatment or control group. Median values for PDC are also much larger than mean 
values for PDC in each of the four groups. In addition, the PDC values are nearly all less 
than 0.8. Figure 3.2 depicts the summary statistics for the adherence rates calculated in 
this study.  
Figure 3.2: Summary Statistics of PDC Values 
 
Bivariable Analyses:  
Tables 3.2 and 3.3 present the bivariable analyses, which allow for the assessment 
of unadjusted associations between the covariates and adherence rates. Table 3.2 exhibits 
the bivariable analyses with the average PDC per patient as the outcome of interest. Table 
3.3 uses the PDC per medication class for each patient as the outcome of interest, and 
includes each medication class examined as a dichotomous covariate. Each of the 
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covariates examined were found to be significantly associated with adherence. PDC is 
significantly associated with time period, where the post-policy time period experienced a 
decrease in the average proportion of days covered corresponding to about 17-22 days of 
therapy. This particular covariate explains a large proportion of the variation in the PDC 
outcome compared to the other covariates, though still very small. Being switched from a 
FFS Medicaid plan to a MCO Medicaid plan (being in the treatment group) increases the 
PDC significantly by about 5 days of therapy.  
The other demographic covariates suggest that being older will increase 
medication adherence, with one additional year leading to one additional day of coverage. 
Age is another variable that explains a large proportion of the variation in the outcome 
compared to the other covariates. Being a male increases medication adherence by about 
15 days throughout the year, and being white increases medication adherence by about 4 
days throughout the year. Alternatively, being black decreases medication adherence by 
about 11 days in a year. Ethnicity is expected to be a confounding variable because there 
are a larger proportion of black patients in the control population. Further, to determine if 
being black and in the control group is different than being black and in the treatment 
group, an interaction term between being black and being in the treatment group was 
added to the final model. Additionally, the variable for white was removed in an attempt 
to consolidate the ethnicity effect into one dichotomous variable. The dichotomous 
variables for each medication class were almost all significantly associated with 
adherence, with the exception of the calcium channel blockers. Patients on thiazide 
diuretics had decreased adherence by about 30 days in a year compared with each of the 
other medication classes. Patients taking biguanides and antihypertensive combinations 
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tend to be less adherent than patients using the other medication classes, as well. Patients 
taking beta-blockers were the most adherent, with about 12 additional days of therapy 
coverage per year. Overall, none of the covariates are largely important predictors of 
adherence based on the explanation of variation in the outcome (R2). Therefore, it is 
likely that the final model will suffer from omitted variable bias.  
Table 3.2: Bivariate Analyses with Average PDC Per Patient as the Outcome of Interest  
(N = 47,056) 
Covariate Estimate Standard Error P-Value R2 
Post-Policy 
Indicator 
-0.04675 0.00219 <0.0001 0.0096 
Treatment Group 
(FFS à MCO) 
0.01386 0.00345 <0.0001 0.0003 
Age (years) 0.00414 0.00012 <0.0001 0.0255 
Male 0.03995 0.00230 <0.0001 0.0064 
White 0.00982 0.00275 0.0004 0.0003 
Black -0.02957 0.00459 <0.0001 0.0009 
PDC = proportion of days covered; FFS = Fee-For-Service; MCO = Managed Care 
Organization 
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Table 3.3: Bivariate Analyses with PDC Per Medication Class Per Patient as the Outcome 
of Interest (N = 109,170) 
Covariate Estimate Standard Error P-Value R2 
Post-Policy 
Indicator 
-0.05941 0.00166 <0.0001 0.0116 
Treatment Group 
(FFS à MCO) 
0.01532 0.00263 <0.0001 0.0003 
Age (years) 0.00438 0.00009 <0.0001 0.0193 
Male 0.03990 0.00174 <0.0001 0.0048 
White 0.01199 0.00206 <0.0001 0.0003 
Black -0.03301 0.00336 <0.0001 0.0009 
ACE Inhibitors 
and Angiotensin II 
Receptor Blockers 
0.01959 0.00203 <0.0001 0.0009 
Beta Blockers 0.03310 0.00211 <0.0001 0.0022 
Calcium Channel 
Blockers 
0.00507 0.00278 0.0684 0.0000 
Thiazide Diuretics -0.08271 0.00317 <0.0001 0.0062 
Antihypertensive 
Combinations 
-0.01296 0.00360 0.0003 0.0001 
HMG-CoA 
Reductase 
Inhibitors (Statins) 
0.01489 0.00198 <0.0001 0.0005 
Biguanides 
(Metformin) 
-0.04476 0.00245 <0.0001 0.0030 
PDC = proportion of days covered; FFS = Fee-For-Service; MCO = Managed Care 
Organization 
 
Multivariable Analyses:  
 
Tables 3.4 and 3.5 present the results from the final multivariate models. The 
multivariate model in Table 3.4 uses average PDC per patient as the outcome of interest, 
and the multivariate model in Table 3.5 uses PDC per medication class per patient as the 
outcome of interest. For each model, the overall R2, or explanation of variation in the 
outcome, was about 0.04 (4%). Therefore, neither model explains a large proportion of 
the variation in the adherence outcome of interest. Again, the variable for being in the 
post-policy period regardless of treatment or control group was significantly associated 
with a decrease in medication adherence by about 17 to 22 days of therapy per year, other 
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factors held constant. In the multivariate model, the variable for being in the treatment 
group is not significantly associated with adherence, nor is the primary outcome of 
interest of being in the post-policy period and being in the treatment group. Each of the 
remaining covariates and interaction terms are significantly associated with adherence. 
Being one year older leads to an increase in medication adherence by 1 to 2 days per 
year, and being male increases medication adherence by about 13 days per year, other 
factors held constant. Being black decreases medication adherence by about 15 days per 
year, on average, if you are in the control population. Being black and being in the 
treatment population leads to a decrease in medication adherence by about 8 days per 
year, instead. Therefore, the existing managed care organization in Region 3 has lower 
medication adherence rates among its black members compared to other black patients in 
the state Medicaid system. 
Each of the effects of the medication classes examined in Table 3.5 was done in 
comparison to biguanide use. Only patients taking thiazide diuretics had lower adherence 
rates than patients taking biguanides, other factors held constant. Patients taking thiazide 
diuretics had on average about 10 fewer days of coverage than patients taking biguanides. 
Patients taking beta-blockers had the highest adherence rates, with about 24 days of 
additional therapy compared with those taking biguanides, other factors held constant. 
Patients taking ACE inhibitors and angiotensin II receptor blockers had the next highest 
adherence rates, with about 20 days of additional therapy compared to patients taking 
biguanides, other factors held constant. Patients taking HMG-CoA reductase inhibitors, 
calcium channel blockers, and antihypertensive combination medications had about 18, 
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15, and 10 days of additional therapy respectively compared to patients taking 
biguanides, other factors held constant.  
Table 3.4: Difference-In-Difference Analysis with Average PDC Per Patient as the 
Outcome of Interest (N=47,056) 
Covariate Estimate Standard Error P-Value 
Intercept 0.51392 0.00773 <0.0001 
Post-Policy 
Indicator 
-0.04862 0.00637 <0.0001 
Treatment Group 
(FFS à MCO) 
 
0.00309 
 
0.00512 
 
0.5488 
Interaction (Post-
Policy Indicator * 
Treatment Group) 
 
 
0.00304 
 
 
0.00677 
 
 
0.6536 
Age (years) 0.00410 0.00012 <0.0001 
Male  0.03818 0.00226 <0.0001 
Black -0.04428 0.00789 <0.0001 
Interaction (Black 
* Treatment 
Group) 
 
0.02448 
 
0.00972 
 
0.0118 
PDC = proportion of days covered; FFS = Fee-For-Service; MCO = Managed Care 
Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
Table 3.5: Difference-In-Difference Analysis with PDC Per Medication Class Per Patient 
as the Outcome of Interest (N=109,170) 
Covariate Estimate Standard Error P-Value 
Intercept 0.47322 0.00656 <0.0001 
Post-Policy 
Indicator 
-0.06037 0.00491 <0.0001 
Treatment Group  
(FFS à MCO) 
 
0.00435 
 
0.00416 
 
0.2952 
Interaction (Post-
Policy Indicator * 
Treatment Group) 
 
 
0.0015 
 
 
0.00521 
 
 
0.7664 
Age (years) 0.00423 0.00009 <0.0001 
Male  0.03545 0.00170 <0.0001 
Black -0.04128 0.00582 <0.0001 
Interaction (Black 
* Treatment 
Group) 
 
0.01936 
0.00714 0.0067 
Medication Class: 
ACE/ARB 
BB 
CCB 
Diuretic 
Combo 
Statin 
Metformin 
 
0.05582 
0.06661 
0.04199 
-0.02837 
0.02755 
0.05015 
reference 
 
0.00285 
0.00291 
0.00342 
0.00374 
0.00408 
0.00281 
reference 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
reference 
PDC = proportion of days covered; FFS = Fee-For-Service; MCO = Managed Care 
Organization; ACE/ARB = ACE Inhibitors and Angiotensin II Receptor Blockers; BB = 
Beta Blockers; CCB = Calcium Channel Blockers; Diuretic = Thiazide Diuretics; Combo 
= Antihypertensive Combinations; Statin = HMG-CoA Reductase Inhibitors (Statins); 
Metformin = Biguanides (Metformin) 
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Section Four: Discussion 
 
To our knowledge, this is the first study that uses medication adherence to 
examine the effect of the switch from Medicaid fee-for-service to managed care in 
Kentucky. This study design was a basic evaluation of the immediate effects of the policy 
implementation. It gives policy makers a basic understanding of the success or failure of 
the Medicaid managed care program after its first year, and allows them to make 
decisions regarding managed care as a viable option for Medicaid patients in Kentucky.  
Descriptive statistics show consistency with the expected demographics of a 
Medicaid population. There is a larger proportion of female members, and Medicaid 
generally enrolls more women of childbearing age than any other demographic group.22 
The control group for this study was located in an urban area in Kentucky, and the 
variable for ethnicity is consistent with the racial population in this area.18 Additionally, 
utilization of certain medication classes were expected, as well. The hypertension 
treatment guidelines recommend initiating ACE inhibitors and angiotensin II receptor 
blockers in white patients due to a more active renin-angiotensin system, and recommend 
calcium channel blockers in black patients due to their less active renin-angiotensin 
system.19 Therefore, the frequencies presented are consistent with the hypertension 
treatment guidelines based on the primary ethnicities in each group. The summary 
statistics of the average PDC variable indicate that most patients have relatively good 
adherence, but there are significant number of patients with very low adherence who pull 
the mean PDC toward zero. Therefore, the distribution is heavy tailed, or negatively 
skewed, indicating a non-parametric distribution. The PDC values presented in Table 3.1 
are nearly all less than 0.8, meaning the average adherence rates for the patients in the 
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study is less than the optimal adherence rate for these chronic medications. This is 
consistent with other studies examining adherence.1,2,4  The large sample size in this study 
allowed for significant non-parametric tests for differences in the baseline characteristics 
among the four groups.  
The demographic variables and medication variables were all significantly 
associated with adherence rates. This information can be leveraged to target populations 
at greater risk of having poor adherence. Most specifically, the black population in an 
urban setting, where managed care has been around since 1997, will take 15 days fewer 
medication compared with other Medicaid patients. Because this is an urban setting, 
access to care is not likely the cause of non-adherence. This particular MCO should 
recognize the importance of targeting these members in hopes to increase adherence and 
decrease disease-related complications. Males in the Kentucky Medicaid program make 
up about one-third of the overall population, but they are taking their medicine 13 more 
days each year than the females. Because females are a large proportion of the Medicaid 
population, they represent a large target for adherence improvement. Finally, patients 
who are taking thiazide diuretics, biguanides, and/or antihypertensive combination 
medications are at greatest risk of having poor adherence rates. Antihypertensive 
combination medications are already a useful tool in encouraging adherence because they 
decrease pill burden. Therefore, they represent a particularly difficult group of patients, 
and arguably the most at risk for developing disease-related complications. Patients 
taking biguanides usually have a large pill burden, due to both the size of the medication 
and the frequency at which it is taken.23 There are extended-release formulations 
available that decrease this pill burden and may help improve adherence. Those patients 
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taking thiazide diuretics have the lowest adherence rates, and it is possibly due to either 
the adverse effects of the medicine (frequent urination), or possibly because their 
provider recommended they use it as needed.23 Technically, the as-needed use of thiazide 
diuretics is off-label,23 but not uncommon. Educational outreach programs, medication 
therapy management services, and provider visits are great ways to encourage each of 
these populations to become more adherent to their long-term medication therapy.  
Multivariable data analyses indicate a decrease in PDC between 0.049 and 0.06 
(17 to 22 fewer days of therapy coverage) after the implementation of Medicaid managed 
care in Kentucky, regardless of reimbursement model, controlling for other factors. When 
comparing those who were impacted by the policy (treatment group) to those who were 
not (control group), there was no significant difference in the average adherence rates, 
other factors held constant. Therefore, at this time, there is clinically inconclusive 
evidence regarding the effect of the implementation of Medicaid managed care in 
Kentucky. There is, however, a need to improve medication adherence among the 
Kentucky Medicaid population. Overall, the state Medicaid program can use the results 
of this study as evidence that additional work needs to be done to improve patient 
outcomes in the Medicaid population.   
 It is arguable that this study suggests that medication persistence is a widespread 
issue, as well. Medication persistence is defined as the duration of time from initiation to 
discontinuation of therapy.8 This study attempted to control for persistence by obtaining 
two separate sample populations of prevalent users in the pre-policy study period and the 
post-policy study period. However, many of the patients in the pre-policy study period 
were also included in the post-policy study period. It is possible that a lower adherence 
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rate in the post-policy study period is related to time to discontinuation of therapy, 
potentially for a legitimate reason that is not documentable in the administrative claims 
dataset. A sensitivity analysis of the data examined the effect of the policy after removing 
outliers. Outliers were considered to be data points two standard deviations away from 
the mean. Several data points from the heavy tail were removed as a result, but the data 
remained non-parametric. Analyses did not lead to any additional explanation of variation 
in the outcome, so the final model included all the data points. Interestingly, this analysis 
led to a significant effect for the interaction between the post-policy study period and the 
treatment group. Adherence rates for those impacted by the policy increased by 3-4 days 
of therapy coverage per year, other factors held constant. Clinically, it is difficult to 
determine whether 3-4 days of therapy per year will significantly change patient 
outcomes. Therefore, additional studies should examine rates of complications as a result 
of missed therapy. Additional sensitivity analyses examined transformations of the data 
in an attempt to remove skewness and provide a true linear model to better determine the 
effect of the covariates on adherence. A quadratic transformed model decreased skewness 
and kurtosis in the data, but the final model is not transformed as this model still 
explained the greatest amount of variation in the outcome.  
Study Strengths and Limitations:  
This is the first study to explore the impact of reimbursement models on quality of 
care in a large population and with a long-term outcome. As previously mentioned, most 
research in this area has been focused on short-term outcomes, within a year of a policy 
change. This study looks beyond a year after the policy implementation, and allows time 
for providers to transition into the new practice model. Additional strengths of this study 
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include the natural quasi-experimental design and the large sample size, which provides 
large power for making statistical inferences. The use of a Medicaid population 
minimizes misclassification of exposure when using administrative claims to determine 
patient outcomes. The Kentucky Medicaid benefit allows for no copay for generic 
products in the medication classes included in this study. Therefore, most patients who 
receive these medications will use their benefit consistently, allowing for accurate capture 
of claims data.  
This study has numerous limitations alongside its strengths. As with any 
observational study using administrative claims data, adherence calculations do not 
actually predict whether or not a patient is taking their medication. Instead, claims data 
just predicts whether or not a patient has medication available to them. If a patient is 
consistently filling their medication at the pharmacy, then it is presumed that true 
adherence approaches the adherence rate calculated from the claims data. Another 
downfall of claims data is the inability to capture primary non-adherence, where a patient 
fails to ever have a prescription filled. The inclusion criteria for this study required that 
patients have a diagnosis code, at least one claim for a medication in the run-in period, 
and at least one claim for a medication in the study period of interest. Therefore, patients 
who never fill their medication are excluded from the study.  
The determination of the adherence measure is also prone to potential bias. The 
calculation was based on the medication generic product identifier (GPI) code. Any 
medications that fall within the same GPI code based on the first 2 to 4 digits in the code 
were considered therapeutically equivalent. Therefore, if a patient were to switch to a 
medication in the same class based on GPI, then this therapy switch would be accounted 
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for. However, if a patient switched to a new medication in a different medication class, 
then this switch is not accounted for. This consideration applies to switches among the 
medication classes indicated for hypertension, and medication classes outside those 
included in this study. Patients that are impacted by this issue are more likely to have 
very small adherence rates. The use of the average PDC was intended to eliminate some 
of this effect. Sensitivity analyses considered removal of outliers to reduce the impact of 
potential switched therapy, but instead led to a reduction in the explanation of variation in 
adherence rate, so these values remained in the model. Finally, the calculation of 
adherence is based on the days supply value recorded in the database. For the post-policy 
study period, in both the treatment and control groups, several missing days supply 
values had to be imputed. These were imputed to 30 days, which was the most common 
days supply recorded in the dataset. This imputation could be a cause of the primary 
difference in adherence between the pre- and post-policy periods.  
Other limitations of this study include the control population, the generalizability 
of the study, the use of both diagnosis codes and medication claims, and the limited data 
available in the post-policy study period. First, the control population was small with 
varying demographic and medication-related variables, and not necessarily the best for 
comparisons to determine the true impact of the policy. The expected effect was that 
adherence in the control population would be higher in the pre-policy study period, but 
similar to the treatment population in the post-policy study period. Instead, the control 
population had generally lower adherence rates than the treatment population throughout 
the study. An alternative control population would be a state close to the state of 
Kentucky that implemented Medicaid managed care before Kentucky, or continues to 
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have a fee-for-service structure. This would allow for a larger sample size to strengthen 
comparisons. The Medicaid structure and population in Kentucky is not necessarily the 
same as that of other states. Therefore, a new control population would have additional 
covariates to consider. Similarly, the results of this study do not imply that Medicaid 
managed care is unsuccessful in improving patient health outcomes.  
Using both diagnosis codes and medication claims as inclusion criteria can limit 
the number of patients included in the study. This was intended to reduce 
misclassification of exposure to the medication if the diagnosis for use is not of interest. 
For example, especially because women of childbearing age are a large proportion of the 
Medicaid population, claims for metformin may be for polycystic ovarian syndrome 
(PCOS) and not type 2 diabetes, as desired. Future studies will test these inclusion criteria 
by including patients with either a diagnosis or a medication claim to determine if results 
are robust. While the follow-up time is a benefit of this study, improvement in adherence 
rates may be an even longer-term outcome, requiring 5 or 10 years of data beyond the 
policy change to determine its true effect. As we continue to obtain data from the 
Kentucky Medicaid dataset, we will continue to test this outcome to determine if 
adherence rates improve in the future.  
Future Directions:  
Subsequent analyses will first examine PDC as a categorical variable to determine 
the change in the percentage of adherent patients in each population. Additionally, 
subsequent analyses will attempt to define a cohort of patients in both the treatment and 
control groups that meet the inclusion criteria in both the pre-policy and post-policy time 
periods. Further studies will examine alternative inclusion criteria, and alternative long-
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term outcomes related to these prevalent chronic disease states, such as hospitalizations 
and mortality rates. These outcomes can be compared to the cost of care under a managed 
care organization model versus a fee-for-service model to determine cost-efficacy. As 
discussed, additional follow-up time may be required to determine the true impact of the 
policy, as changes in adherence rates may not have a clinically significant effect for 
several years after such a policy change.  
Conclusions:  
Results indicate clinically inconclusive evidence regarding the immediate effect 
of the implementation of Medicaid managed care in Kentucky on medication adherence 
rates in patients with prevalent chronic diseases. There is a need to address the decline in 
average adherence rates, and the efficacy of Medicaid managed care based on medication 
adherence. 
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Appendix A: Kentucky Medicaid Regions of Coverage  
 
This map is a representation of Medicaid coverage in 2016. Prior to the implementation 
of Medicaid managed care in November 2011, only Region 3 (red) had an available 
Medicaid managed care plan: Passport Health. The statewide area excluding Region 3 
(blue) was entirely fee-for-service reimbursement.  
 
Photo Credit: Kentucky Cabinet for Health and Family Services: Department for 
Medicaid Services: Medicaid Member Managed Care Organization Option Information 
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Appendix B: ICD-9 Diagnosis Codes for Hypertension, Hypercholesterolemia, and Type 
2 Diabetes 
 
Prevalent Chronic Disease ICD-9-CM Diagnosis Codes 
Hypertension 401.1, 401.9 
Hypercholesterolemia 272.0, 272.1, 272.2, 272.3, 272.4 
Type 2 Diabetes 250.00, 250.02, 250.10, 250.12, 250.20, 250.22, 250.30, 
250.32, 250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 
250.70, 250.72, 250.80, 250.82, 250.90, 250.92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
Appendix C: Medication Classes and GPI Codes Indicated First-Line for Hypertension, 
Hypercholesterolemia, and Type 2 Diabetes 
 
Prevalent Chronic Disease Medication Class  GPI Code 
Hypertension ACE inhibitors and angiotensin II 
receptor blockers  
361xxxxxxx 
Beta-blockers 33xxxxxxxx 
Calcium channel blockers 34xxxxxxxx 
Thiazide diuretics 376xxxxxxx 
Antihypertensive combination 
medications 
369xxxxxxx 
Hypercholesterolemia HMG-CoA reductase inhibitors 
(statins) 
39xxxxxxxx 
Type 2 Diabetes Biguanides (metformin) 2725xxxxxx 
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Appendix D: List of Variables, Model Specification, and Graphical Representation of the 
Expected Difference-In-Difference Model  
 
Final Model:  Yi = β0 + β1Ii(Post-Policy Indicator) + β2Ii(Treatment Group) + β3Ii(Post-
Policy Indicator * Treatment Group) + β4Agei + β5Ii(Male) + β6Ii(Black) + β7Ii(Black * 
Treatment Group) + β8Ii(Medication Class: ACE inhibitors and angiotensin II receptor 
blockers) + β9Ii(Medication Class: beta-blockers) + β10Ii(Medication Class: calcium 
channel blockers) + β11Ii(Medication Class: thiazide diuretics) + β12Ii(Medication Class: 
antihypertensive combination medications) + β13Ii(Medication Class: HMG-CoA 
reductase inhibitors) + εi 
 
Here are the statistical null and alternative hypotheses of primary interest:        H0: β3 = 0 
                            H1: β3 ≠ 0 
Specifically, the null hypothesis is that the policy implementing Medicaid managed care 
has no impact on adherence rates in the treatment group. The alternative hypothesis is 
that the policy implementing Medicaid managed care impacts adherence rates in the 
treatment group.  
 
Yi is the primary outcome of interest, or adherence as measured by the proportion of days 
covered (PDC). PDC is in the final model shown above represents the PDC per 
medication class per patient.  
 
Covariates used in the Final Model:  
1. Post-Policy Indicator à dichotomous variable where patients in the post-policy 
period = 1, and patients in the pre-policy time period = 0.  
2. Treatment Group à dichotomous variable where patients impacted by the policy 
(FFS à MCO) = 1, and patients in the Region 3 MCO = 0.  
3. Post-Policy Indicator * Treatment Group à interaction term where patients in the 
post-policy treatment group = 1, and patients in all other groups = 0.  
4. Age à continuous variable representing patient age in years  
5. Male à dichotomous variable where male patients = 1, and female patients = 0.  
6. Black à dichotomous variable where black patients = 1, and all other races = 0.  
7. Black * Treatment Group à interaction term where black patients in the 
treatment group only = 1, and all other patients = 0.  
8. Medication Class: ACE inhibitors and angiotensin II receptor blockers à patients 
with medication claims for ACE inhibitors and angiotensin II receptor blockers 
9. Medication Class: beta-blockers à patients with medication claims for beta-
blockers 
10. Medication Class: calcium channel blockers à patients with medication claims 
for calcium channel blockers 
11. Medication Class: thiazide diuretics à patients with medication claims for 
thiazide diuretics  
12. Medication Class: antihypertensive combination medications à patients with 
medication claims for antihypertensive combination medications 
13. Medication Class: HMG-CoA reductase inhibitors à patients with medication 
claims for HMG-CoA reductase inhibitors 
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Covariates not used in the Final Model:  
1. White à dichotomous variable where white patients = 1, and all other races = 0.  
2. Medication Class: Biguanides à patients with medication claims for biguanides 
(used as the reference population in the final model).  
 
εi represents the error term, or the leftover variation in the response variable (Yi) that the 
explanatory variables in the model cannot explain. More specifically, it is the difference 
in the observed and predicted response of adherence to the policy implementation.  
 
Graphical Representation of Expected Difference-In-Difference Model:  
 
 
 
Control Group: Expected change in adherence for the Region 3 MCO 
• The expected change in adherence is a slight increase for this managed care 
population with good baseline adherence rates  
 
Treatment Group: Expected change in adherence for those impacted by the policy 
• The expected change in adherence is a significant increase for patients who were 
receiving FFS in the pre-policy period, and are now receiving managed care in the 
post-policy period.  
 
No Policy Change: Expected change in adherence rates if no policy was implemented 
• The expected change in adherence is a slight increase for this fee-for-service 
population with poor baseline adherence rates  
 
The difference-in-difference model will determine the true change in adherence rates for 
the treatment group while accounting for changes in adherence that happen naturally after 
a fixed period of time, as represented by the control group. It is expected that the policy 
change will increase adherence rates to near that of the control group for this study.  
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